Completed PHASE2 INTERVENTIONAL 3-arm NCT04616430

Topical Endoxifen in Women (CREME)

Karma CREME-1: A Double-blind, Placebo-controlled, Three-armed, Pilot Study of the Effects, Safety and Tolerability of Topical Endoxifen in Women Within the Karma Cohort

Sponsor: Atossa Therapeutics, Inc.

Conditions Mammographic Breast Density

Interventions Placebo Topical endoxifen

Updated 9 times since 2020 Last updated: Jun 17, 2021 Started: Apr 9, 2018 Primary completion: Sep 10, 2018 Completion: Sep 4, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Mammographic Breast Density and is currently completed. Atossa Therapeutics, Inc. leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Nov 2022 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Dec 2021 — Nov 2022 [monthly]

Completed PHASE2
Sep 2021 — Dec 2021 [monthly]

Completed PHASE2
Jan 2021 — Sep 2021 [monthly]

Completed PHASE2
Dec 2020 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Atossa Therapeutics, Inc.
Karolinska Institutet

Data source: Atossa Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stockholm, Sweden